

Vijay K Chopra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2160938/publications.pdf>

Version: 2024-02-01

18
papers

10,794
citations

567281

15
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

6310
citing authors

#	ARTICLE	IF	CITATIONS
1	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
2	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
3	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
4	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017932.	3.7	3
5	Global Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007901.	3.9	25
6	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
7	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2020, 9, e012199.	3.7	55
8	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
9	Consensus and development of document for management of stabilized acute decompensated heart failure with reduced ejection fraction in India. <i>Indian Heart Journal</i> , 2020, 72, 477-481.	0.5	2
10	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	27.0	2,821
11	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	2.2	90
12	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	7.4	340
13	Anaemia, iron deficiency and heart failure in 2020: facts and numbers. <i>ESC Heart Failure</i> , 2020, 7, 2007-2011.	3.1	63
14	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
15	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	27.0	4,108
16	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.1	264
17	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
18	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018, 6, e1008-e1018.	6.3	113